Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05097274
Other study ID # CCR4131
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 15, 2015
Est. completion date December 31, 2025

Study information

Verified date April 2024
Source Institute of Cancer Research, United Kingdom
Contact Rosalind A Eeles, FRCP FRCR
Phone 44 208 661 3642
Email rosalind.eeles@icr.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the study is to determine if PET-CT imaging (using contrast recommended in clinical guidelines) is superior to combined bone scan and MRI/CT of the abdomen & pelvis in detecting the increased incidence of metastasis (nodal/distant outside the pelvis) in men with prostatic carcinoma with germline BRCA mutations.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Confirmed pathogenic germline mutation in either BRCA1 or BRCA2 - Over the age of 18 - Diagnosed with prostate cancer and at a time when staging imaging is clinically indicated; either: - At a new diagnosis - Biochemically progressing patients who were treated radically with surgery or radiotherapy (more than 6 months ago) and are currently not receiving hormonal treatment or chemotherapy - Patients on active surveillance with a PSA doubling time of 6 months or less Exclusion Criteria: - Diagnosis of other malignancy (excluding basal cell cancer/squamous cell cancer of the skin) within five years of diagnosis - Known metastatic prostate cancer, both local and distant - Patients who have received any oncological treatment within the last six months - Patients on any investigational drug treatment - Patients on steroids - Known history of inflammatory/infective diseases (e.g. sarcoidosis, tuberculosis, inflammatory bowel disease) - Contraindications to having an MRI using the standard MRI checklist (e.g. pacemakers, aneurysm clips, claustrophobia)

Study Design


Intervention

Other:
MRI pelvis or CT imaging under clinical management for Pr Ca
Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images.
Whole body bone scan imaging
bone scan of the whole body (under clinical diagnosis).
PET-CT imaging
Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.

Locations

Country Name City State
United Kingdom Cancer Genetics Unit, Royal Marsden Hospital London Sutton, Surrey

Sponsors (3)

Lead Sponsor Collaborator
Institute of Cancer Research, United Kingdom Cancer Research UK, National Institute for Health Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other To investigate the rate of incidentally detected second primary tumours in BRCA mutation carriers with prostate cancer Within 12 months of the last FCH-PET-CT scan
Other To investigate the prognostic significance of FCH-PET-CT findings (e.g. employing standard SUV parameters and heterogeneity of PET texture of the primary prostate tumour) Within 12 months of the last FCH-PET-CT scan
Other To assess agreement between imaging readers in assessing FCH-PET-CT scans. Within 12 months of the last FCH-PET-CT scan
Primary 1. Sensitivity of FCH-PET-CT scan To determine if the sensitivity of FCH-PET-CT is superior to combined conventional imaging (MRI (T2 and T1 weighted)/CT and bone scan) in detecting nodal and distant (outside the pelvis) metastases in BRCA1/2 germline mutation carriers with prostate cancer. Within 12 months of the last FCH-PET-CT scan
Secondary 2. Outline the Specificity of the FCH-PET-CT scan determining the positive predictive value (PPV) and negative predictive value (NPV) in detecting metastatic disease in BRCA mutation carriers with prostate cancer Within 12 months of the last FCH-PET-CT scan
Secondary 3.Incidence and sites of additional metastases identified on FCH-PET-CT compared with combined MRI/bone scan. Within 12 months of the last FCH-PET-CT scan
Secondary 4.To measure the impact of FCH-PET-CT findings in changing patient management and in clinical decision making Within 12 months of the last FCH-PET-CT scan
See also
  Status Clinical Trial Phase
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A